SCHEMBL18239070

SCHEMBL18239070

ClN1CCCC(c2ccccn2)C1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD4 P21917 2/20 0.47
MAP4K4 O95819 1/20 0.47
HSD11B1 P28845 1/20 0.47
SPR P35270 1/20 0.45
USP30 Q70CQ3 1/20 0.42
DGAT2 Q96PD7 1/20 0.42
KDM5A P29375 1/20 0.41
ALDH1A1 P00352 1/20 0.41
MAPT P10636 1/20 0.41
OPRM1 P35372 1/20 0.41
OPRD1 P41143 1/20 0.41
OPRK1 P41145 1/20 0.41
OPRL1 P41146 1/20 0.41
PRMT5 O14744 2/20 0.40
WDR77 Q9BQA1 2/20 0.40
CHRM2 P08172 1/20 0.40
CHRM4 P08173 1/20 0.40
CHRM5 P08912 1/20 0.40
CHRM1 P11229 1/20 0.40
CHRM3 P20309 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10274489 0.81 KCNH2 (0.52) DRD4MAP4K4HSD11B1SPRUSP30
SCHEMBL6351706 0.81 DRD4 (0.47) DRD4MAP4K4HSD11B1SPRUSP30
SCHEMBL13490514 0.79 CYP3A4 (0.58) DRD4ALDH1A1
SCHEMBL17886898 0.77 DRD4 (0.45) DRD4MAP4K4HSD11B1SPRUSP30
SCHEMBL17896380 0.77 DRD2 (0.47) DRD4MAP4K4HSD11B1SPRKDM5A
SCHEMBL19016266 0.77 DRD4 (0.45) DRD4MAP4K4HSD11B1SPRUSP30
SCHEMBL6347014 0.77 HSD11B1 (0.53) DRD4MAP4K4HSD11B1SPRUSP30
SCHEMBL31754520 0.77 USP30 (0.59) DRD4MAP4K4HSD11B1USP30
SCHEMBL1515110 0.77 ALDH1A1 (0.46) DRD4MAP4K4HSD11B1SPRALDH1A1
SCHEMBL1481510 0.77 ALDH1A1 (0.50) DRD4MAP4K4HSD11B1ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9708336-B2 Metallo-beta-lactamase inhibitors MERCK SHARP & DOHME CORP. (US) 2017-07-18 US disclosed
US-20160333021-A1 METALLO-BETA-LACTAMASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2016-11-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160333021-A1 METALLO-BETA-LACTAMASE INHIBITORS MGAM, MGAM2, GAA DRD4 4518/4885MAP4K4 4071/4885HSD11B1 401/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.